Causeway Sensors, a Belfast, Northern Ireland-based developer of a platform for rapid accurate diagnosis, raised £1.2m in funding.
The round was led by the Bank of Ireland Kernel Capital Growth Fund (NI) with participation from Qubis and private investors and further funding secured from Innovate UK.
The company will use the funds to grow the team, develop the technology and explore new market opportunities.
Led by Dr. Bob Pollard, CEO, Causeway Sensors has developed a novel method of distinguishing between a viral and bacterial infection in a real-time point-of-care setting, enabling a reduction in the ineffective use of antibiotics for viral infections. Its nanostructure chip platform allows high levels of sensitivity and specificity in the detection of infectious diseases without the high cost infrastructure and expertise of a modern pathology laboratory.
The company is a Queens University Belfast (QUB) spin-out.